Core Insights - The medical device CDMO sector in China is experiencing significant growth driven by policy support and surging demand, with expectations to replicate the successful trajectory of the pharmaceutical CXO model over the next five years [1][7]. Policy Support - The Chinese medical device market is projected to reach 1.2 trillion yuan by 2024, indicating robust growth potential [2]. - Global leaders in the medical device industry have long outsourced production to specialized CDMO providers to enhance R&D efficiency and reduce time-to-market for new products [2]. - The implementation of the MAH system allows R&D companies to outsource production, providing a significant policy boost to the industry [3]. Industry Demand - There is a growing demand for CDMO services in high-end medical equipment sectors, particularly in surgical robotics, where innovative companies require robust support for product commercialization [5]. - The medical device CDMO market is expected to grow rapidly, with a projected annual compound growth rate of 16.3% from 2020 to 2025, significantly outpacing the overall medical device industry growth [2]. Company Developments - Companies like Meihua Medical are actively expanding their CDMO capabilities, offering comprehensive services from product development to mass delivery across various medical device segments [4]. - The establishment of high-end medical device CDMO platforms, such as Shuimu Dongfang, is facilitating the acceleration of product development and market entry for innovative projects [5]. Market Trends - The Chinese medical device CDMO sector is transitioning from a focus on specific segments like IVD to a broader range of product lines and full-service capabilities [7]. - The industry is characterized by a fragmented landscape with a focus on specialized, high-quality services rather than large-scale operations [6]. Future Outlook - The next 3-5 years are critical for the industry, with expectations for the emergence of 1-2 leading companies capable of providing integrated services from R&D to mass production [9]. - Key growth areas include high-value consumables, automated filling and sterilization platforms, and the development of accelerators for prototype registration and small batch production [7].

Core Viewpoint - The stock of Meihao Medical (301363) has shown a slight decline, with recent trading data indicating mixed capital flows and performance metrics compared to industry averages [1][2][3]. Group 1: Stock Performance - As of October 16, 2025, Meihao Medical's stock closed at 23.13 yuan, down 0.04%, with a trading volume of 57,800 hands and a total transaction amount of 134 million yuan [1]. - The net inflow of main funds on October 16 was 13.05 million yuan, accounting for 9.72% of the total transaction amount, while retail investors experienced a net outflow of 10.73 million yuan, representing 8.00% of the total [1][2]. Group 2: Financial Metrics - Meihao Medical's total market value is 13.158 billion yuan, with a net asset of 3.595 billion yuan and a net profit of 114 million yuan [3]. - The company's revenue for the first half of 2025 was 733 million yuan, a year-on-year increase of 3.73%, while the net profit decreased by 32.44% to 114 million yuan [3]. - The gross profit margin stands at 37.52%, which is significantly lower than the industry average of 51.85% [3]. Group 3: Industry Comparison - In terms of valuation, Meihao Medical has a price-to-earnings ratio of 57.56, which is lower than the industry average of 66.63, and a price-to-book ratio of 3.66, compared to the industry average of 3.81 [3]. - The company ranks 25th in total market value and 42nd in net assets within the medical device industry [3]. Group 4: Analyst Ratings - Over the past 90 days, 17 institutions have rated Meihao Medical, with 15 buy ratings and 2 hold ratings, indicating a generally positive outlook [4]. - The average target price set by institutions for the stock is 24.42 yuan [4].

Group 1 - On October 16, a total of 13 companies had their restricted shares unlocked, with a total unlock volume of 938 million shares [1] - The total market value of the unlocked shares is approximately 22.01 billion yuan based on the latest closing prices [1] - The companies with the highest unlock volumes are Meihao Medical, Shangda Shares, and Zhongtung High-tech, with unlock volumes of 217 million shares, 207 million shares, and 189 million shares respectively [1] Group 2 - In terms of unlock market value, Shangda Shares, Meihao Medical, and Minglida lead with market values of 6.781 billion yuan, 5.021 billion yuan, and 3.882 billion yuan respectively [1] - The companies with the highest proportion of unlocked shares relative to total share capital are Guanlong Energy Saving, Shangda Shares, and Minglida, with unlock ratios of 66.93%, 55.68%, and 42.12% respectively [1]

证券之星消息，截至2025年10月15日收盘，美好医疗(301363)报收于23.14元，上涨2.71%，换手率 3.48%，成交量5.44万手，成交额1.25亿元。 10月15日的资金流向数据方面，主力资金净流入195.35万元，占总成交额1.57%，游资资金净流出 630.18万元，占总成交额5.06%，散户资金净流入434.83万元，占总成交额3.49%。 近5日资金流向一览见下表： 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-15 | 23.14 2.71% | 195.35万 | 1.57% | -630.18万 | -5.06% | 434.83万 | 3.49% | | 2025-10-14 | 22.53 -3.22 ...

Core Viewpoint - Meihao Medical's stock price has shown volatility, with a slight increase recently, but a decline over the past five trading days and year-to-date. The company operates in the medical device sector, focusing on the design, development, manufacturing, and sales of medical equipment components [1][2]. Financial Performance - For the first half of 2025, Meihao Medical reported a revenue of 733 million yuan, representing a year-on-year growth of 3.73%. However, the net profit attributable to shareholders decreased by 32.44% to 114 million yuan [2]. - Since its A-share listing, Meihao Medical has distributed a total of 248 million yuan in dividends [3]. Stock Market Activity - As of October 15, Meihao Medical's stock price was 22.99 yuan per share, with a market capitalization of 13.078 billion yuan. The stock has experienced a year-to-date decline of 0.49% and a significant drop of 8.19% over the last five trading days [1]. - The stock has been featured on the "Dragon and Tiger List" twice this year, with the most recent appearance on August 25 [1]. Shareholder Structure - As of September 19, the number of shareholders for Meihao Medical was 15,000, a decrease of 7.94% from the previous period. The average number of circulating shares per shareholder increased by 8.63% to 10,418 shares [2]. - The top shareholders include Huabao Zhongzheng Medical ETF and several new institutional investors, indicating a shift in the shareholder base [3].

Group 1 - The stock price of Meihao Medical (301363) closed at 23.28 yuan on October 13, 2025, down by 2.1% with a turnover rate of 3.54% and a trading volume of 55,200 shares, amounting to a transaction value of 128 million yuan [1][2] - On October 13, the net outflow of main funds was 15.3741 million yuan, while retail investors saw a net inflow of 17.8014 million yuan [2] Group 2 - Meihao Medical announced that 412,300,000 shares, accounting for 72.4769% of the total share capital, will be released from restrictions and listed for trading on October 16, 2025 [1][2] - The total share capital of the company is 568,871,180 shares, and the shareholders applying for the release of restrictions have complied with relevant commitments without any non-operational fund occupation or illegal guarantees [1]

Core Viewpoint - Meihua Medical (301363) announced the lifting of restrictions on shares issued prior to its initial public offering, allowing for the circulation of a significant portion of its total shares [1] Group 1 - The number of restricted shares being released is 412,300,000, which accounts for 72.4769% of the company's total share capital [1] - The number of shareholders involved in this release is five [1] - The lifting of restrictions will take effect on October 16, 2025, which is 36 months after the company's initial public offering [1]

证券代码：301363 证券简称：美好医疗 公告编号：2025-067 深圳市美好创亿医疗科技股份有限公司 关于首次公开发行前已发行股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次解除限售的股份为深圳市美好创亿医疗科技股份有限公司（以下简 称"公司"、"发行人"）首次公开发行前已发行的股份。本次解除限售股东户数 共计5户，解除限售股份数量为412,300,000股，占公司总股本的72.4769%，限售 期为自公司首次公开发行股票并上市之日起36个月。 2、本次解除限售股份的上市流通日期为2025年10月16日（星期四）。 一、公司首次公开发行和股本变动情况 根据中国证券监督管理委员会《关于同意深圳市美好创亿医疗科技股份有限 公司首次公开发行股票注册的批复》（证监许可〔2022〕1441号）和深圳证券交 易所《关于深圳市美好创亿医疗科技股份有限公司人民币普通股股票在创业板上 市的通知》（深证上〔2022〕986号），公司首次向社会公众公开发行人民币普 通股（A股）4,427万股，并于2022年10月12日在深圳证券交 ...

关于深圳市美好创亿医疗科技股份有限公司 首次公开发行前已发行股份解除限售并上市流通 的核查意见 东兴证券股份有限公司（以下简称"东兴证券"或"保荐机构"）作为深圳 市美好创亿医疗科技股份有限公司（以下简称"美好医疗"、"上市公司"或"公 司"）首次公开发行股票并在创业板上市的保荐机构，根据《证券发行上市保荐 业务管理办法（2025 年修订）》《深圳证券交易所创业板股票上市规则（2025 年 修订）》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作（2025 修订）》等相关法律、法规和规范性文件的规定，对美好医疗首次公 开发行前已发行股份解除限售并上市流通事项进行了核查，具体情况如下： 一、公司首次公开发行和股本变动情况 根据中国证券监督管理委员会《关于同意深圳市美好创亿医疗科技股份有限 公司首次公开发行股票注册的批复》（证监许可〔2022〕1441 号）和深圳证券交 易所《关于深圳市美好创亿医疗科技股份有限公司人民币普通股股票在创业板上 市的通知》（深证上〔2022〕986 号），公司首次向社会公众公开发行人民币普通 股（A 股）4,427 万股，并于 2022 年 10 月 12 ...

Core Viewpoint - On October 10, Meihao Medical experienced a decline of 1.82% with a transaction volume of 111 million yuan, indicating a high level of trading activity and investor interest in the stock [1] Financing Summary - On October 10, Meihao Medical had a financing buy-in amount of 15.31 million yuan and a financing repayment of 11.07 million yuan, resulting in a net financing buy-in of 4.24 million yuan [1] - As of October 10, the total financing and securities lending balance for Meihao Medical was 194 million yuan, with the financing balance accounting for 5.20% of the circulating market value, which is above the 90th percentile level over the past year [1] - The company had no shares repaid in securities lending on October 10, with 1,300 shares sold short, amounting to 30,900 yuan at the closing price [1] - The securities lending balance was 986,400 yuan, also exceeding the 90th percentile level over the past year [1] Company Overview - Meihao Medical, established on July 15, 2010, and listed on October 12, 2022, is located in Longgang District, Shenzhen, Guangdong Province, specializing in the design, development, manufacturing, and sales of medical device components [2] - The main revenue sources for Meihao Medical include home respiratory machine components (59.48%), home and consumer electronics components (14.61%), other medical product components (10.33%), cochlear implant components (8.16%), precision molds and automation equipment (5.63%), and other categories (1.09%) [2] - For the first half of 2025, Meihao Medical reported a revenue of 733 million yuan, a year-on-year increase of 3.73%, while the net profit attributable to the parent company was 114 million yuan, a year-on-year decrease of 32.44% [2] Dividend and Shareholder Information - Since its A-share listing, Meihao Medical has distributed a total of 248 million yuan in dividends [3] - As of June 30, 2025, the top ten circulating shareholders included Huabao Zhongzheng Medical ETF (512170) as the second-largest shareholder with 5.694 million shares, an increase of 1.6179 million shares from the previous period [3] - New shareholders include Rongtong Health Industry Flexible Allocation Mixed A/B (000727) with 5 million shares, and several other funds have increased their holdings, while some have exited the top ten list [3]